Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.

ABSTRACT:

SUBMITTER: Kubasch AS 

PROVIDER: S-EPMC7214242 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature